Vaughan Nelson Investment Management L.P. lessened its position in Hologic, Inc. (NASDAQ:HOLX) by 63.0% during the 3rd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 172,490 shares of the medical equipment provider’s stock after selling 293,385 shares during the quarter. Vaughan Nelson Investment Management L.P. owned about 0.07% of Hologic worth $11,465,000 as of its most recent SEC filing.
A number of other institutional investors also recently made changes to their positions in the stock. ArrowMark Colorado Holdings LLC acquired a new stake in Hologic during the second quarter worth $88,797,000. Deerfield Management Company L.P. Series C purchased a new stake in shares of Hologic in the 2nd quarter valued at about $78,101,000. Point72 Asset Management L.P. lifted its holdings in shares of Hologic by 1,409.8% in the 2nd quarter. Point72 Asset Management L.P. now owns 1,182,513 shares of the medical equipment provider’s stock valued at $67,403,000 after purchasing an additional 1,104,193 shares during the last quarter. MUFG Securities EMEA plc lifted its holdings in shares of Hologic by 1,199.9% in the 2nd quarter. MUFG Securities EMEA plc now owns 942,000 shares of the medical equipment provider’s stock valued at $53,694,000 after purchasing an additional 869,531 shares during the last quarter. Finally, Avidity Partners Management LP purchased a new stake in shares of Hologic in the 2nd quarter valued at about $46,580,000. Hedge funds and other institutional investors own 93.69% of the company’s stock.
Several research firms have recently weighed in on HOLX. Zacks Investment Research raised Hologic from a “hold” rating to a “buy” rating and set a $72.00 target price for the company in a report on Monday, November 2nd. UBS Group boosted their target price on Hologic from $77.00 to $81.00 and gave the company a “neutral” rating in a report on Thursday, November 5th. ValuEngine downgraded Hologic from a “hold” rating to a “sell” rating in a research note on Friday, November 6th. Wells Fargo & Company upped their price objective on Hologic from $80.00 to $90.00 and gave the company an “overweight” rating in a research note on Thursday, November 5th. Finally, Raymond James upped their price objective on Hologic from $75.00 to $86.00 and gave the company an “outperform” rating in a research note on Thursday, November 5th. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eleven have assigned a buy rating to the stock. Hologic currently has a consensus rating of “Buy” and a consensus price target of $77.56.
NASDAQ HOLX opened at $71.07 on Tuesday. The company has a current ratio of 1.47, a quick ratio of 1.17 and a debt-to-equity ratio of 1.22. The business’s 50 day moving average is $68.78 and its two-hundred day moving average is $61.16. Hologic, Inc. has a 12-month low of $26.49 and a 12-month high of $77.49. The stock has a market capitalization of $18.41 billion, a price-to-earnings ratio of 16.92, a PEG ratio of 1.04 and a beta of 1.39.
Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, November 4th. The medical equipment provider reported $2.07 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $1.22 by $0.85. The company had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.11 billion. Hologic had a return on equity of 47.83% and a net margin of 29.53%. The firm’s quarterly revenue was up 55.6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.65 EPS. Equities analysts forecast that Hologic, Inc. will post 4.33 earnings per share for the current fiscal year.
Hologic Company Profile
Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, surgical products, and light-based aesthetic and medical treatment systems for women in the United States and internationally. The company offers Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima quantitative viral load tests for HIV, Hepatitis C, and Hepatitis B; ThinPrep System for use in cytology applications; Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth; and various diagnostic tests for acute respiratory ailments.
Featured Story: Cost of equity and a company’s balance sheet
Want to see what other hedge funds are holding HOLX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Hologic, Inc. (NASDAQ:HOLX).
Receive News & Ratings for Hologic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hologic and related companies with MarketBeat.com's FREE daily email newsletter.